Home » The 7.1 billion yuan fixed increase of Xiaokang shares was approved, and the stock price limit reached a new high this year_Company_New Energy_Sales

The 7.1 billion yuan fixed increase of Xiaokang shares was approved, and the stock price limit reached a new high this year_Company_New Energy_Sales

by admin
The 7.1 billion yuan fixed increase of Xiaokang shares was approved, and the stock price limit reached a new high this year_Company_New Energy_Sales

Original title: Xiaokang shares 7.1 billion yuan fixed increase approved share price limit hit a new high this year

On the evening of June 10, Xiaokang (601127) announced that the China Securities Regulatory Commission approved the company’s non-public issuance of no more than about 163 million new shares, valid for 12 months.

On June 10, Xiaokang shares closed at 71.52 yuan, the daily limit, a new high this year, with a turnover rate of 4.03% and a total market value of 97.263 billion yuan.

Xiaokang shares planned to raise no more than 7.13 billion yuan in this fixed increase. Based on the calculation of about 163 million shares, the company’s fixed increase price should be above 43.74 yuan per share. In June 2021, Xiaokang shares will be increased for the first time, with a non-public offering of about 56.3689 million shares, the issue price is 46.00 yuan per share, and the net amount of funds raised is about 2.568 billion yuan.

According to the plan, the company’s fundraising will be invested in “electric vehicle model development and product platform technology upgrade project”, “factory intelligent upgrade and electric drive production line construction project”, “user center construction project” and supplementary working capital.

Through the implementation of the above projects, the company will continue to increase investment in research and development. In addition to upgrading existing models to develop more new product lines, it will also develop a new generation model platform that is more compatible and expandable to better support the entire vehicle. products; and carry out forward-looking technology research and development work around the development trend of new energy vehicles. In terms of process quality improvement, we will introduce advanced automation, information-based production and testing equipment at home and abroad, such as visual inspection systems, in Liangjiang Factory and Phoenix Factory, build high-efficiency, high-power-density electric-driven and highly flexible production lines, and further improve the level of automated production and product competition. force.

See also  Banks, fleeing deposits and latent losses: Charles Schwab Bank is now in the crosshairs

The implementation of the user center construction project will help the company to further develop offline marketing channels and service systems, and expand the popularity and market influence of new energy vehicle brands such as AITO and SERES. By supplementing working capital, it will also effectively ease the financial pressure and meet the working capital turnover needs after the expansion of the business scale in the future.

According to the production and sales report of Xiaokang Co., Ltd. in May 2022, the company’s sales of new energy vehicles surpassed that of fuel vehicles for the first time in that month, achieving sales of 10,452 vehicles, a year-on-year increase of 244%.

Among them, the sales volume of its high-end smart new energy vehicle, the Celis, reached 5,440 units in May, a year-on-year increase of 1616% and a month-on-month increase of 58.19%, far exceeding expectations. From January to May this year, the cumulative production and sales of new energy vehicles of Xiaokang Co., Ltd. reached 36,206 and 33,204 units, respectively, a year-on-year increase of 259% and 212%. Among them, the cumulative production and sales of Celis reached 15,583 units and 13,923 units, an increase of 1328% and 1344%.

The fixed growth rate of Xiaokang shares is fast this time. On January 26 this year, the board of directors launched the fixed increase plan. It only took about 4 and a half months from the review of the issuance review committee on May 23 to the official approval of the China Securities Regulatory Commission on June 10.

Upstream news reporter Zhong HeReturn to Sohu, see more

See also  Asia-Pacific Pharmaceuticals: The company's shareholding structure is relatively dispersed and there is a risk of changes in the controlling rights

Editor:

Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy